Cythemias
News
Health Canada approves ruxolitinib for PV
Image courtesy of AFIP Health Canada has approved the JAK1/2 inhibitor ruxolitinib (Jakavi) for the control of hematocrit in adult patients with...
News
Development of myelofibrosis drug on hold
The US Food and Drug Administration (FDA) has placed a full clinical hold on trials conducted under the investigational new drug application for...
News
MF drug trials placed on partial clinical hold
The US Food and Drug Administration (FDA) has placed a partial clinical hold on trials conducted under the investigational new drug (IND)...
News
Generic imatinib launched with savings program
Photo by Rhoda Baer Sun Pharma has announced the US launch of imatinib mesylate tablets, which are a generic version of Novartis’s Gleevec, for...
News
EHA creates ‘roadmap’ for hematology research
Photo by Daniel Sone The European Hematology Association (EHA) has created a “roadmap” for hematology research in Europe. This guidance document...
News
Protein’s role in thrombosis elucidated
Image by Andre E.X.
News
Team identifies potential target for XLP-1
Image courtesy of NIAID A protein called diacylglycerol kinase alpha (DGKα) could be a therapeutic target for X-linked lymphoproliferative...
Conference Coverage
BM fibrosis grade may impact OS in PMF
ORLANDO, FL—Having a higher grade of bone marrow (BM) fibrosis may confer inferior overall survival (OS) in patients with primary myelofibrosis (...
Conference Coverage
Five-year data suggest ruxolitinib improves survival in MF
ASH Annual Meeting Photo courtesy of ASH ORLANDO, FL—Five-year results from the COMFORT-II trial appear to confirm that treatment with...
News
FDA approves generic imatinib
Photo by Steven Harbour The US Food and Drug Administration (FDA) has approved the use of imatinib mesylate, a generic version of Novartis’s...
News
Team characterizes EMH niche
Image by John Perry Previous studies have shown that hematopoietic stresses—such as myelofibrosis, anemia, and myeloablation—can induce...